Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)


Vermersch P., Eralinna J. -. , Nicholas R., Oreja-Guevara C., Siva A., Van Wijmeersch B., et al.

35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS, Stockholm, İsveç, 11 - 13 Eylül 2019, cilt.25, ss.344-345

  • Cilt numarası: 25
  • Basıldığı Şehir: Stockholm
  • Basıldığı Ülke: İsveç
  • Sayfa Sayısı: ss.344-345